Bone Density and Menstruation
Research Study
We are investigating whether two medications, romosozumab and zoledronic acid, affect bone density and strength when combined with estrogen and progesterone in women who have stopped having menstrual periods. If you’ve started missing periods recently or stopped having them altogether, you could be eligible for this study.
Please call 434-982-0871 or email misralab@uvahealth.org for more information!
Fast Facts
Fewer than 3 periods in the past 6 months
Girls & women ages
14-30
Compensation
up to $1,550
Conducted in
Charlottesville, VA at UVA
Additional Information
Amenorrhea, or not having menstrual periods, is correlated with a loss of bone density. Right now, there are no FDA-approved therapies to treat bone loss in young adult women who have stopped having menstrual periods or who are having too few periods.
Romosozumab and zoledronic acid are already FDA approved for treating low bone density and osteoporosis in postmenopausal women. This research study is testing whether these two medications, in combination with estrogen and progesterone, can increase bone density and strength in young adult women who have stopped having periods or have very few periods.
You (or your teen) may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Girls and women aged 14-30
- Fewer than 3 periods in the past 6 months
- Have already had a first period
- Below-average bone density
- Dental check-up within the past year
- Willing to use birth control for the study’s duration
Exclusion Criteria:
- Currently pregnant, breastfeeding, or planning to become pregnant
- Currently smoke cigarettes
- Planned invasive dental procedure or major surgery within the next 18 months
- Medical history of any of the following:
- Cardiac problems, strokes, kidney disease, liver disease, Cushing’s disease, diabetes, thyroid disease, blood clots or clotting disorders, migraines with aura, cancer, Paget’s disease, eating disorders, PCOS, primary ovarian insufficiencies, osteonecrosis of the jaw, substance abuse, immunodeficiency disorders, immunosuppressive therapy, oral steroid use
Visits
This study involves 9 visits over the course of 12 months. These visits will include history and physical exams, blood draws, questionnaires about your exercise and eating habits, DXA scans (which measure bone health and body composition), and XCT scans (which evaluate the structure of the bones in your wrist and leg).
Treatments
- If you’re eligible and choose to participate, you will be randomly assigned to either the romosozumab or placebo group (in a 2:1 ratio, meaning you are two times more likely to receive the active medication than the placebo, or inactive medication).
- You will receive monthly subcutaneous injections of romosozumab or placebo, which will be administered at your study visits at UVA. These injections are given from a pen device similar to an insulin pen.
- You’ll also receive self-adhesive estrogen patches (100 micrograms/day) to apply twice weekly. These patches can be worn while doing your daily activities, including showering.
- We will also provide oral progesterone pills for 12 days each month (to balance the effects of estrogen and prevent thickening of the uterine lining), as well as daily calcium and vitamin D supplements.
- In addition, all participants will receive a single infusion of zoledronic acid at the 6-month visit.
As a participant, you may receive up to $1,550 for completing the entire study. In addition, we will help cover transportation costs. For local participants, transportation costs will be reimbursed up to $25 per visit (such as Uber fares or gas mileage). For participants traveling from farther away, compensation will be provided at 70 cents per mile, up to $150 per visit.
All study-related tests are provided at no cost.
There is no cost for you to participate in our research study.